BioWorld MedTech

Dec. 14, 2016

FDA gives green light to Lumendi's new platform to treat colonic lesions

With an eye toward promoting minimally invasive procedures and treating colorectal disease within a patient's intestine, Westport, Conn.-based Lumendi LLC has scored a win at the U.S. FDA with its new device. Read More

Chinese patents continue torrid pace, med-tech is a key area of progress

Gone fishing: Blackfynn's data platform likely lure for partners in neurology

Varian revs up for public spin off of imaging business

FDA strikes more measured tone in emerging signals final

Other news to note

Appointments and advancements

Product briefs

Daily M&A

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for Feb. 11, 2025.

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...

News in brief

BioWorld Asia

BioWorld Asia briefs for Feb. 10, 2026

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...